Growing Use Cases: Recent clinical trials have shown that GLP-1RAs can also support reducing cardiovascular risk and heart failure-related symptoms and slow down the progression of kidney diseases
Triple agonists that are being developed to target three Gs (GLP-1, GIP, and glucagon) may also help increase metabolism
I think people dont realize that when we do podcasts and Instagram and all this stuff is, is, uh, its a lot of work to create content, especially well researched content
This issue came to the fore in early 2024 when the UK MHRA issued a National Patient Safety Alert triggered by global supply issues for certain GLP-1 drugs, advising healthcare professionals to conserve existing stock for patients with Type 2 diabetes.6,7 The implementation of such measures ensures that the critical priority of patient needs continues to be met, while also avoiding patients seeking what the WHO describes as falsified or substandard versions of these medicines through unregulated outlets on the internet.8 Looking to the future, demand for GLP-1 drugs is expected to remain high as healthcare systems look to manage obesity and diabetes among an ageing population
So, its a very individualized approach
